| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10914615 | Molecular Oncology | 2014 | 7 Pages |
Abstract
Our data suggest that patients belonging to the “HER2-enriched” subtype and/or having high H2T/p95 protein expression ratio are exquisitely sensitive to anti-HER2 agents. MBC patients with these tumors could be candidates for studies aimed at establishing chemotherapy-free regimens.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Filippo Montemurro, Aleix Prat, Valentina Rossi, Giorgio Valabrega, Jeff Sperinde, Caterina Peraldo-Neia, Michela Donadio, Patricia Galván, Anna Sapino, Massimo Aglietta, José Baselga, Maurizio Scaltriti,